A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Head and Neck Cancer|Cervical Cancer|Endometrial Cancer|Triple Negative Breast Cancer|Ovarian Cancer|Soft Tissue Sarcoma|Melanoma|Nasopharyngeal Carcinoma|Non Small Cell Lung Cancer|Classic Hodgkin Lymphoma
Interventions: DRUG: ILB-2109|DRUG: Toripalimab
Sponsor: Innolake Biopharm